Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine
Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine
Abstract BackgroundResponding to SARS-CoV-2 Delta variants escaped the vaccine-induced immunity and waning immunity from the inactivated whole virus vaccine, Thailand recently proposed a heterologous inactivated whole virus vaccine (CoronaVac) viral vector vaccine (ChAdOx1 nCoV-19) prime-boost vaccine regimen(I/V). This study aims to evaluate the immunogenicity and adverse events of this regimen by comparison with homologous CoronaVac, ChAdOx1 nCoV-19, and convalescent serum. MethodImmunogenicity was evaluated by the level of IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (S1 subunit) (anti-S RBD). At 2 weeks following the second dosage, a selection of random samples was tested for plaque reduction neutralisation (PRNT) and Pseudotype-Based Microneutralization test (PVNT) against SARS-CoV-2 variants of concern (VOCs). The safety profile of heterologous CoronaVac-ChAdOx1 nCoV-19 prime-boost vaccine regimen was described by interviewing at the 1-month visit. ResultBetween April to August 2021,426 participants were included in the study, with 155 obtaining CoronaVac-ChAdOx1 nCoV-19(I/V),32 obtaining homologous CoronaVac(I/I),47 obtaining homologous ChAdOx1 nCoV-19(V/V),169 with history covid-19 infection. Geometric mean titers (GMTs) of anti-S RBD level in the I/V group compare 2wks and 4 wks (873.9 vs 639,p=0.00114).At 4 wks, GMTs of anti-S RBD level in I/V group was 639, 95% CI 63-726,and natural infection group 177.3, 95% CI 42-221, and V/V group 211.1, 95% CI 77-152, and I/I group 108.2, 95% CI 77-152 ; all p<0.001).At 2 wks, The GMTs of 50%PRNT of 19 sampling from the I/V group is 434.5, 95% CI 326-579, against wild type and 80.4, 95% CI 56-115, against alpha and 67.4, 95% CI 48-95, against delta and 19.8, 95% CI 14-30, against beta; all p<0.001. At 2 wks, The GMTs of 50%PVNT of 15 sampling from the I/V group is 597.8, 95% CI 368-970, against wild type and 163.9, 95% CI 89-301, against alpha and 157.7, 95% CI 66-378, against delta. The AEs in the I/V schedule were well tolerated and generally unremarkable. ConclusionThe I/V vaccination is a mixed regimen that induced higher immunogenicity and shall be considered for responding to Delta Variants when only inactivated whole virus vaccine and viral vector vaccine was available.
Sawaengdee Warittha、Ritthitham Kanokphon、Pinyosukhee Nadthanan、Wichajarn Rattanawadee、Dhepaksorn Panadda、Khunphon Athiwat、Rojanawiwat Archawin、Wichuckchinda Nuanjun、Wanitchang Asawin、Thawong Penpitcha、Mahasirimongkol Surakameth、Pimpapai Warangluk、Phainupong Daraka、Jongkaewwattana Anan、Soonthorncharttrawat Sakulrat、Chumpol Supaporn、Piboonsiri Pundharika、Srisutthisamphan Kanjana、Iamsiritahworn Sopon、Sapsutthipas Sompong、Phumiamorn Supaporn、Wichaidit Minkwan、Puangtubtim Wiroj、Kwangsukstid Oraya、Somporn Thitiporn
Medical Life Sciences Institute, Department of Medical SciencesInstitute of Biological Products, Department of Medical Sciences NonthaburiMedical Life Sciences Institute, Department of Medical SciencesMedical Life Sciences Institute, Department of Medical SciencesMedical Life Sciences Institute, Department of Medical SciencesMedical Life Sciences Institute, Department of Medical SciencesNational Institute of HealthMedical Life Sciences Institute, Department of Medical SciencesVirology and Cell technology Research Team, National Center for Genetic Engineering and Biotechnology(BIOTEC), National Science and Technology Development Agency (NSTDA)Medical Life Sciences Institute, Department of Medical SciencesMedical Life Sciences Institute, Department of Medical SciencesMedical Life Sciences Institute, Department of Medical SciencesInstitute of Dermatology, Department of Medical ServiceVirology and Cell technology Research Team, National Center for Genetic Engineering and Biotechnology(BIOTEC), National Science and Technology Development Agency (NSTDA)Medical Life Sciences Institute, Department of Medical SciencesInstitute of Biological Products, Department of Medical Sciences NonthaburiMedical Life Sciences Institute, Department of Medical SciencesVirology and Cell technology Research Team, National Center for Genetic Engineering and Biotechnology(BIOTEC), National Science and Technology Development Agency (NSTDA)Division epidemiology, Department of disease controlInstitute of Biological Products, Department of Medical Sciences NonthaburiInstitute of Biological Products, Department of Medical Sciences NonthaburiInstitute of Dermatology, Department of Medical ServiceMedical Life Sciences Institute, Department of Medical SciencesInstitute of Dermatology, Department of Medical ServiceInstitute of Biological Products, Department of Medical Sciences Nonthaburi
预防医学医学研究方法基础医学
Sawaengdee Warittha,Ritthitham Kanokphon,Pinyosukhee Nadthanan,Wichajarn Rattanawadee,Dhepaksorn Panadda,Khunphon Athiwat,Rojanawiwat Archawin,Wichuckchinda Nuanjun,Wanitchang Asawin,Thawong Penpitcha,Mahasirimongkol Surakameth,Pimpapai Warangluk,Phainupong Daraka,Jongkaewwattana Anan,Soonthorncharttrawat Sakulrat,Chumpol Supaporn,Piboonsiri Pundharika,Srisutthisamphan Kanjana,Iamsiritahworn Sopon,Sapsutthipas Sompong,Phumiamorn Supaporn,Wichaidit Minkwan,Puangtubtim Wiroj,Kwangsukstid Oraya,Somporn Thitiporn.Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine[EB/OL].(2025-03-28)[2025-08-02].https://www.medrxiv.org/content/10.1101/2021.11.05.21264700.点此复制
评论